Shares of NeuroDerm Ltd. (NASDAQ:NDRM) saw an uptick in trading volume on Monday . 114,193 shares were traded during trading, an increase of 73% from the previous session’s volume of 65,946 shares.The stock last traded at $18.44 and had previously closed at $18.81.

Separately, Roth Capital reaffirmed a “buy” rating on shares of NeuroDerm in a report on Sunday, May 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $24.70.

The company’s market capitalization is $395.66 million. The firm’s 50 day moving average price is $16.94 and its 200 day moving average price is $15.48.

NeuroDerm (NASDAQ:NDRM) last announced its quarterly earnings results on Thursday, May 26th. The company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.10. On average, analysts predict that NeuroDerm Ltd. will post ($1.52) earnings per share for the current year.

NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease; ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa, and ND0680 for the treatment of a small subset of severe Parkinson’s disease patients, whose symptoms have advanced to a severe stage, requiring even higher doses of LD/CD than ND0612H is designed to provide.